During the past decade, Gyeonggi-Do Clinical Site1 conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gyeonggi-Do Clinical Site1" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Gyeonggi-Do Clinical Site1" are "Gastric Cancer" (2 trials) and "Pan-tumor" (1 trials). Many other conditions were trialed in "Gyeonggi-Do Clinical Site1" in a lesser frequency.

Most popular intervention types in "Gyeonggi-Do Clinical Site1" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Capecitabine" (2 trials), "ONO-4538" (2 trials), "Oxaliplatin" (2 trials), "Placebo" (2 trials) and "Nivolumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gyeonggi-Do Clinical Site1" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Gyeonggi-Do Clinical Site1". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Gyeonggi-Do Clinical Site1, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Gyeonggi-Do Clinical Site1, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".